Pfizer and J&J end development of Alzheimer's drug

Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.

The companies say their bapineuzumab did not improve cognition or mental function in patients with mild to moderate Alzheimer's disease when compared to placebo. It was hoped that bapineuzumab would reduce the decline in physical and mental function for patients with Alzheimer's. Current treatments can only temporarily ease symptoms of the disease.

The two companies said July 23 that the drug had failed in a different trial. All other studies are being discontinued, and Johnson & Johnson said it will take a charge of $300 million to $400 million in the third quarter.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Alzheimer's drug fails in 1 study, 2nd continues (Update)

Jul 23, 2012

(AP) — A closely watched experimental Alzheimer's treatment has failed to slow the disease in one late-stage study, a big disappointment for doctors and patients but not the end of the road for the drug. Pfizer Inc. ...

Alzheimer's drug shows promise in early trial

Jul 18, 2012

(HealthDay News) -- Researchers say an investigational drug helped improve memory, language, attention and other mental skills in people with early Alzheimer's disease.

Eli Lilly halts development of Alzheimer's drug

Aug 17, 2010

(AP) -- Eli Lilly and Co. has stopped developing a potential Alzheimer's disease treatment at a time when the drugmaker is searching wide and far for new drugs to fill a large revenue hole that will form starting next year.

Recommended for you

The long reach of Alzheimer's disease

Apr 08, 2014

To address the burgeoning demands of Alzheimer's disease that will affect generations, new policies will have to be adopted to acknowledge the complex and unique needs of people with dementia.

User comments